ArticleClinical & developmental immunology2007
Soluble triggering receptor expressed on myeloid cells 1 is released in patients with stable chronic obstructive pulmonary disease.
Article in Clinical & developmental immunology, 2007. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 32 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
32 citing papers in PubMed, 67 citations in OpenAlex.
- Sputum and blood transcriptomics characterisation of the inhaled PDE4 inhibitor CHF6001 on top of triple therapy in patients with chronic bronchitis.Respiratory research · 2020Trial
- Change of walking distance in intermittent claudication: impact on inflammation, oxidative stress and mononuclear cells: a pilot study.Clinical research in cardiology : official journal of the German Cardiac Society · 2015Trial
- Pancreatic stone protein as a novel marker for neonatal sepsis.Intensive care medicine · 2013Trial
- Article
- Triggering Receptor Expressed on Myeloid Cells-1 (TREM-1) in Inflammation and Disease: Mechanisms, Therapeutic Potential, and Future Directions.International journal of molecular sciences · 2025Review
- Association of serum levels of soluble triggering receptor expressed on myeloid cells-1 with endothelial dysfunction in patients with type 2 diabetes.Frontiers in clinical diabetes and healthcare · 2025Article
- Clinical value of serum sTREM-1 and HBP levels in combination with traditional inflammatory markers in diagnosing hospital-acquired pneumonia in elderly.BMC infectious diseases · 2022Article
- Peripheral Blood Mononuclear Cell Gene Expression in Chronic Obstructive Pulmonary Disease: miRNA and mRNA Regulation.Journal of inflammation research · 2022Article
- TREM-1 aggravates chronic obstructive pulmonary disease development via activation NLRP3 inflammasome-mediated pyroptosis.Inflammation research : official journal of the European Histamine Research Society ... [et al.] · 2021Article
- Dynamic Monitoring of sTREM-1 and Other Biomarkers in Acute Cholangitis.Mediators of inflammation · 2020Article
- Therapeutic Effect of Modulating TREM-1 via Anti-inflammation and Autophagy in Parkinson's Disease.Frontiers in neuroscience · 2019Article
- TREM-1; Is It a Pivotal Target for Cardiovascular Diseases?Journal of cardiovascular development and disease · 2018Review
- Soluble Triggering Receptor Expressed on Myeloid Cells 1 in lung cancer.Scientific reports · 2018Article
- TREM-1 Contributes to Inflammation in IgA Nephropathy.Kidney diseases (Basel, Switzerland) · 2018Article
- Article
- TREM-1 promotes intestinal tumorigenesis.Scientific reports · 2017Article
- Increased expression of triggering receptor expressed on myeloid cells-1 in the population with obesity and insulin resistance.Obesity (Silver Spring, Md.) · 2017Article
- TREM-1 SNP rs2234246 regulates TREM-1 protein and mRNA levels and is associated with plasma levels of L-selectin.PloS one · 2017Article
- TREM-1 links dyslipidemia to inflammation and lipid deposition in atherosclerosis.Nature communications · 2016Article
- Electronic cigarette inhalation alters innate immunity and airway cytokines while increasing the virulence of colonizing bacteria.Journal of molecular medicine (Berlin, Germany) · 2016Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 4 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Chronic obstructive pulmonary disease (COPD) is increasingly recognized as a systemic disease that is associated with increased serum levels of markers of systemic inflammation. The triggering receptor expressed on myeloid cells 1 (TREM-1) is a recently identified activating receptor on neutrophils, monocytes, and macrophage subsets. TREM-1 expression is upregulated by microbial products such as the toll-like receptor ligand lipoteichoic acid of Gram-positive or lipopolysaccharides of Gram-negative bacteria. In the present study, sera from 12 COPD patients (GOLD stages I-IV, FEV1 51 +/- 6%) and 10 healthy individuals were retrospectively analyzed for soluble TREM-1 (sTREM-1) using a newly developed ELISA. In healthy subjects, sTREM-1 levels were low (median 0.25 ng/mL, range 0-5.9 ng/mL). In contrast, levels of sTREM-1 in sera of COPD patients were significantly increased (median 11.68 ng/mL, range 6.2-41.9 ng/mL, P<.05). Furthermore, serum levels of sTREM-1 showed a significant negative correlation with lung function impairment. In summary, serum concentrations of sTREM-1 are increased in patients with COPD. Prospective studies are warranted to evaluate the relevance of sTREM-1 as a potential marker of the disease in patients with COPD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.